PortalPublikationenLong-term outcome analysis of reduced-intensity allogeneic s...

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

Standard

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. / Robinson, Stephen P; Boumendil, Ariane; Finel, Herve; Peggs, Karl S; Chevallier, Patrice; Sierra, Jorge; Finke, Jürgen; Poiré, Xavier; Maillard, Natacha; Milpied, Noël; Yakoub-Agha, Ibrahim; Koh, Mickey; Kröger, Nicolaus; Nagler, Arnon; Koc, Yener; Dietrich, Sascha; Montoto, Silvia; Dreger, Peter.

in: BONE MARROW TRANSPL, Jahrgang 53, Nr. 5, 05.2018, S. 617-624.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Robinson, SP, Boumendil, A, Finel, H, Peggs, KS, Chevallier, P, Sierra, J, Finke, J, Poiré, X, Maillard, N, Milpied, N, Yakoub-Agha, I, Koh, M, Kröger, N, Nagler, A, Koc, Y, Dietrich, S, Montoto, S & Dreger, P 2018, 'Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party', BONE MARROW TRANSPL, Jg. 53, Nr. 5, S. 617-624. https://doi.org/10.1038/s41409-017-0067-3

APA

Robinson, S. P., Boumendil, A., Finel, H., Peggs, K. S., Chevallier, P., Sierra, J., Finke, J., Poiré, X., Maillard, N., Milpied, N., Yakoub-Agha, I., Koh, M., Kröger, N., Nagler, A., Koc, Y., Dietrich, S., Montoto, S., & Dreger, P. (2018). Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. BONE MARROW TRANSPL, 53(5), 617-624. https://doi.org/10.1038/s41409-017-0067-3

Vancouver

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. BONE MARROW TRANSPL. 2018 Mai;53(5):617-624. https://doi.org/10.1038/s41409-017-0067-3

Bibtex

@article{434d6077386d4a05a9c95b6a6fe437c6,
title = "Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party",
abstract = "Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.",
keywords = "Journal Article",
author = "Robinson, {Stephen P} and Ariane Boumendil and Herve Finel and Peggs, {Karl S} and Patrice Chevallier and Jorge Sierra and J{\"u}rgen Finke and Xavier Poir{\'e} and Natacha Maillard and No{\"e}l Milpied and Ibrahim Yakoub-Agha and Mickey Koh and Nicolaus Kr{\"o}ger and Arnon Nagler and Yener Koc and Sascha Dietrich and Silvia Montoto and Peter Dreger",
year = "2018",
month = may,
doi = "10.1038/s41409-017-0067-3",
language = "English",
volume = "53",
pages = "617--624",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

AU - Robinson, Stephen P

AU - Boumendil, Ariane

AU - Finel, Herve

AU - Peggs, Karl S

AU - Chevallier, Patrice

AU - Sierra, Jorge

AU - Finke, Jürgen

AU - Poiré, Xavier

AU - Maillard, Natacha

AU - Milpied, Noël

AU - Yakoub-Agha, Ibrahim

AU - Koh, Mickey

AU - Kröger, Nicolaus

AU - Nagler, Arnon

AU - Koc, Yener

AU - Dietrich, Sascha

AU - Montoto, Silvia

AU - Dreger, Peter

PY - 2018/5

Y1 - 2018/5

N2 - Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.

AB - Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.

KW - Journal Article

U2 - 10.1038/s41409-017-0067-3

DO - 10.1038/s41409-017-0067-3

M3 - SCORING: Journal article

C2 - 29335632

VL - 53

SP - 617

EP - 624

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -